Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
Allurion Technologies (NYSE:ALUR) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $2.50 price target on the stock.
Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
Allurion Technologies Inc (ALUR) Q3 2025 Earnings Call Highlights: Strategic Restructuring and ... [Yahoo! Finance]